Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Esophagus
Published in: Esophagus 4/2014

01-09-2014 | Original Article

Clinical features and prognostic factors of brain metastasis from esophageal carcinoma

Authors: Akihiko Okamura, Hiroya Takeuchi, Hiroyuki Sako, Rieko Nakamura, Tsunehiro Takahashi, Norihito Wada, Hirofumi Kawakubo, Yoshiro Saikawa, Tai Omori, Soji Ozawa, Yuko Kitagawa

Published in: Esophagus | Issue 4/2014

Login to get access

Abstract

Background

Brain metastasis from esophageal carcinoma is uncommon. The aims of this study were to assess the frequency of brain metastasis from esophageal carcinoma, describe treatment modalities and their outcomes, and determine predictors of survival.

Methods

Between 2004 and 2012, 680 patients with esophageal carcinoma were registered at Keio University Hospital, Tokyo, Japan. Of these patients, 16 (2.3 %) were diagnosed with brain metastasis. We reviewed their medical records and performed statistical analyses.

Results

The median survival after diagnosis of brain metastasis was 5.0 months (95 % CI 1.2–8.7 months). The only statistically significant baseline characteristic that predicted worse survival from brain metastasis was the onset form of brain metastasis (p = 0.01). At the onset of brain metastasis, the median survival from brain metastasis was 13.0 months (95 % CI 0.0–31.0 months) in patients without extracranial metastasis and 2.0 months (95 % CI 0.0–4.3 months) in patients with extracranial metastasis (p = 0.01).

Conclusions

Approximately 2 % patients with esophageal carcinoma were diagnosed with brain metastasis. The prognosis of brain metastasis is extremely poor, but long-term survival may be expected with intensive treatment for brain metastasis when the first metastatic site is the brain.
Literature
1.
Gabrielsen TO, Eldevik OP, Orringer MB, Marshall BL. Esophageal carcinoma metastatic to the brain: clinical value and cost-effectiveness of routine enhanced head CT before esophagectomy. Am J Neuroradiol. 1995;16:1915–21.PubMed
2.
Sueyama H, Yamanoi T, Uematu T, Saitou M, Sakai K, et al. Brain metastases from esophageal cancers: clinical features and treatment results. Nihon Igaku Hoshasen Gakkai Zasshi. 2001;61:534–9.PubMed
3.
Ogawa K, Toita T, Sueyama H, Fuwa N, Kakinohana Y, et al. Brain metastases from esophageal carcinoma: natural history, prognostic factors, and outcome. Cancer. 2002;94:759–64.PubMedCrossRef
4.
Tsujie M, Shibata N, Nomura T, Tanaka T, Morimoto T, et al. A patient with stage IVb small cell carcinoma of the esophagus who survived 23 months after systemic cancer chemotherapy. Gan To Kagaku Ryoho. 2003;30:271–5.PubMed
5.
Weinberg JS, Suki D, Hanbali F, Cohen ZR, Lenzi R, et al. Metastasis of esophageal carcinoma to the brain. Cancer. 2003;98:1925–33.PubMedCrossRef
6.
Kesler KA, Hammoud ZT, Helft PR, Rieger KM, Pritz MB, et al. Long-term survival after excision of a solitary esophageal cancer brain metastasis. J Thorac Cardiovasc Surg. 2006;131:497–8.PubMedCrossRef
7.
8.
Agrawal R, Shukla P, Shukla V, Chauhan A. Brain metastasis from esophageal carcinoma. J Cancer Res Ther. 2009;5:137–9.PubMedCrossRef
9.
Kanemoto A, Hashimoto T, Harada H, Asakura H, Ogawa H, et al. Occurrence and clinical features of brain metastasis after chemoradiotherapy for esophageal carcinoma. J Radiat Res. 2011;52:509–15.PubMedCrossRef
10.
11.
Song Z, Lin B, Shao L, Zhang Y. Brain metastases from esophageal cancer: clinical review of 26 cases. World Neurosurg. 2013;81:131–5.PubMedCrossRef
12.
Seyoum N, G/Selassie K, Kasshun A. Squamous cell carcinoma of the esophagus presenting with features of intracranial space occupying lesion. Ethiop Med J. 2012;50:201–4.PubMed
13.
Iijima S, Makari Y, Kato T, Ooshima S, Hoshi M, et al. A case of a 14-month survival patient on advanced esophageal cancer with uncontrolled brain metastasis completely responding to nedaplatin, adriamycin, plus 5-FU (NAF) therapy. Gan To Kagaku Ryoho. 2009;36:2052–4.PubMed
14.
Almasi S, Bashashati M, Rezaei N, Markazi-Moghaddam N. Brain metastasis from esophageal carcinoma. Neurol India. 2004;52:492–3.PubMed
15.
Schuster JM, Rostomily RC, Hahn C, Winn HR. Two cases of esophageal carcinoma metastatic to the pineal region with a review of the literature. Surg Neurol. 1998;49:100–2.PubMedCrossRef
16.
Biswal BM, Lal P. Brain metastasis as first presentation on carcinoma of the esophagus–a case report. Indian J Med Sci. 1995;49:210–1.PubMed
17.
Bosch A, Frias Z, Caldwell WL, Jaeschke WH. Autopsy findings in carcinoma of the esophagus. Acta Radiol Oncol Radiat Phys Biol. 1979;18:103–12.PubMedCrossRef
18.
Mandard AM, Chasle J, Marnay J, Villedieu B, Bianco C, et al. Autopsy findings in 111 cases of esophageal cancer. Cancer. 1981;48:329–35.PubMedCrossRef
19.
Anderson LL, Lad TE. Autopsy findings in squamous-cell carcinoma of the esophagus. Cancer. 1982;50:1587–90.PubMedCrossRef
20.
Sobin LH, Gospodarowicz MK, Wittekind C, editors. International Union against Cancer TNM Classification of Malignant Tumours, 7th Edition, Oesophagus including Oesophagogastric Junction. New York: Wiley; 2009. p. 66–72.
21.
Crooks V, Waller S, Smith T, Hahn TJ. The use of the Karnofsky Performance Scale in determining outcomes and risk in geriatric outpatients. J Gerontol. 1991;46:M139–44.PubMedCrossRef
22.
Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol. 1984;2:187–93.PubMed
23.
Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37:745–51.PubMedCrossRef
24.
25.
Kalkanis SN, Kondziolka D, Gaspar LE, Burri SH, Asher AL, et al. The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96:33–43.PubMedCentralPubMedCrossRef
26.
Gaspar LE, Mehta MP, Patchell RA, Burri SH, Robinson PD, et al. The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96:17–32.PubMedCentralPubMedCrossRef
27.
Linskey ME, Andrews DW, Asher AL, Burri SH, Kondziolka D, et al. The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96:45–68.PubMedCentralPubMedCrossRef
28.
Mehta MP, Paleologos NA, Mikkelsen T, Robinson PD, Ammirati M, et al. The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96:71–83.PubMedCentralPubMedCrossRef
29.
Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363:1665–72.PubMedCrossRef
30.
Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006;295:2483–91.PubMedCrossRef
31.
Tew WP, Kelsen DP, Ilson DH. Targeted therapies for esophageal cancer. Oncologist. 2005;10:590–601.PubMedCrossRef
32.
Mehta AI, Brufsky AM, Sampson JH. Therapeutic approaches for HER2-positive brain metastases: circumventing the blood–brain barrier. Cancer Treat Rev. 2013;39:261–9.PubMedCrossRef
Metadata
Title
Clinical features and prognostic factors of brain metastasis from esophageal carcinoma
Authors
Akihiko Okamura
Hiroya Takeuchi
Hiroyuki Sako
Rieko Nakamura
Tsunehiro Takahashi
Norihito Wada
Hirofumi Kawakubo
Yoshiro Saikawa
Tai Omori
Soji Ozawa
Yuko Kitagawa
Publication date
01-09-2014
Publisher
Springer Japan
Published in
Esophagus / Issue 4/2014
Print ISSN: 1612-9059
Electronic ISSN: 1612-9067
DOI
https://doi.org/10.1007/s10388-014-0434-8

Other articles of this Issue 4/2014

Esophagus 4/2014 Go to the issue

Original Article

Is there room for improvement in esophageal cancer surgery? Results of a prospective protocol for individualization of surgical treatment

Original Article

Cytoplasmic hepatocyte growth factor immunoreactivity predicting lymph node metastasis in esophageal squamous cell carcinoma

Case Report

Hyperosmolar hyperglycemic nonketotic coma after chemoradiotherapy for esophageal cancer

Original Article

Treatment results of laparoscopic surgery in Japanese patients with upside-down stomach

Original Article

Clinical implications of quantitative pathological and immunohistochemical markers for lymph node metastasis in esophageal cancer patients based on preoperative treatment status

Case Report

Esophagectomy and combined lobectomy with a covering latissimus dorsi muscle flap for an esophagopulmonary fistula due to advanced esophageal cancer: report of two cases
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits